Antibiotic exposure in prenatal and early life and risk of juvenile idiopathic arthritis: a nationwide register-based cohort study.


Journal

RMD open
ISSN: 2056-5933
Titre abrégé: RMD Open
Pays: England
ID NLM: 101662038

Informations de publication

Date de publication:
08 2023
Historique:
received: 23 05 2023
accepted: 02 08 2023
medline: 1 9 2023
pubmed: 31 8 2023
entrez: 30 8 2023
Statut: ppublish

Résumé

Early antibiotic exposure influences the gut microbiota which is believed to be involved in the pathogenesis of juvenile idiopathic arthritis (JIA). We aimed to investigate the association between systemic antibiotics in prenatal and early life and risk of JIA. We conducted a register-based cohort study including all children born in Norway from 2004 through 2012. The children were followed until 31 December 2020. Main exposures were dispensed antibiotics to the mother during pregnancy and to the child during 0-24 months of age. The outcome was defined by diagnostic codes indicating JIA. Multivariate logistic regression analyses were performed to estimate the association between antibiotic exposure and JIA. We included 535 294 children and their mothers in the analyses; 1011 cases were identified. We found an association between exposure to systemic antibiotics during 0-24 months and JIA (adjusted OR (aOR) 1.40, 95% CI 1.24 to 1.59), with a stronger association for >1 course (aOR 1.50, 95% CI 1.29 to 1.74) vs 1 course (aOR 1.31, 95% CI 1.13 to 1.53). Subanalyses showed significant associations in all age periods except 0-6 months, and stronger association with sulfonamides/trimethoprim and broad-spectrum antibiotics. There was no association between prenatal antibiotic exposure and JIA. The novel observation of no association with prenatal antibiotic exposure and JIA suggests that the association between antibiotics in early life and JIA is unlikely to be confounded by shared family factors. This may indicate that exposure to antibiotics in early life is an independent risk factor for JIA.

Identifiants

pubmed: 37648397
pii: rmdopen-2023-003333
doi: 10.1136/rmdopen-2023-003333
pmc: PMC10471866
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: SH: none declared, SA has received travel funding from Ferring pharmaceuticals., HS: none declared, KS: none declared.

Références

Pediatrics. 2015 Aug;136(2):e333-43
pubmed: 26195533
Front Immunol. 2021 May 13;12:683022
pubmed: 34054875
J Rheumatol. 2015 Mar;42(3):521-6
pubmed: 25320218
Nat Rev Dis Primers. 2022 Jan 27;8(1):5
pubmed: 35087087
EBioMedicine. 2023 Jul;93:104654
pubmed: 37329576
Joint Bone Spine. 2014 Mar;81(2):112-7
pubmed: 24210707
Pediatr Rheumatol Online J. 2022 Apr 11;20(1):25
pubmed: 35410419
Clin Exp Rheumatol. 1998 Jan-Feb;16(1):99-101
pubmed: 9543575
Scand J Public Health. 2020 Feb;48(1):49-55
pubmed: 31288711
Tidsskr Nor Laegeforen. 2020 Oct 07;140(14):
pubmed: 33070589
Tidsskr Nor Laegeforen. 2017 Oct 02;137(18):
pubmed: 28972334
Open Access Rheumatol. 2019 Nov 06;11:253-267
pubmed: 31807094
Gut Microbes. 2021 Jan-Dec;13(1):1-18
pubmed: 33651651
J Rheumatol. 2003 Oct;30(10):2275-82
pubmed: 14528529
Pediatr Rheumatol Online J. 2021 Sep 16;19(1):145
pubmed: 34530851
Tidsskr Nor Laegeforen. 2002 Oct 30;122(26):2546-9
pubmed: 12522882
Lancet. 2007 Mar 3;369(9563):767-778
pubmed: 17336654
Pediatr Res. 2023 Mar;93(4):1096-1104
pubmed: 35854091
Sci Rep. 2021 Feb 9;11(1):3422
pubmed: 33564018
Pediatr Rheumatol Online J. 2021 Aug 23;19(1):135
pubmed: 34425842
Eur J Epidemiol. 2014 Aug;29(8):551-8
pubmed: 24407880
Science. 2016 Apr 29;352(6285):539-44
pubmed: 27126036
J Clin Med. 2021 Jan 25;10(3):
pubmed: 33504109
J Autoimmun. 2019 Mar;98:1-12
pubmed: 30638708
Immunol Rev. 2020 Mar;294(1):9-26
pubmed: 31833578
Rheumatology (Oxford). 2022 Feb 2;61(2):514-530
pubmed: 34382060
World J Pediatr. 2021 Feb;17(1):40-51
pubmed: 32533534

Auteurs

Sigrid Hestetun (S)

Department of Rheumatology, Oslo University Hospital, Oslo, Norway sigridhestetun@yahoo.no.
Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.

Svend Andersen (S)

Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Department of Paediatrics, Vestfold Hospital Trust, Tønsberg, Norway.

Helga Sanner (H)

Department of Rheumatology, Oslo University Hospital, Oslo, Norway.
Department of Health Sciences, Oslo New University College, Oslo, Norway.

Ketil Størdal (K)

Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.
Paediatric Research Institute, Faculty of Medicine, University of Oslo, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH